Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. Biokine’s lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in Phase IIa clinical trial for the treatment of refractory and relapsed Acute Myeloid Leukemia (AML), as well as a Phase I clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. Biokine has a knowhow technologies, and a pipeline for the development of therapeutics targeting cancer. Biokine intends to advance the development of its pipeline into the clinic by establishing collaborations with other companies and conducting fundraising activities from private and public agencies.

Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.

Zeneca is a British multinational pharmaceutical company focused on therapeutic oncology and cardiovascular products. Zeneca was established in June 1993 through a demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries. In 1999 Zeneca and Astra AB, a Sweden-based pharmaceutical company, merged to form AstraZeneca plc.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

NovaScreen Biosciences Corp., a subsidiary of Caliper Life Sciences, Inc., is a company headquartered in Hanover, MD. The firm develops commercial research and drug discovery devices. It was acquired by Caliper Life Sciences, Inc. on October 04, 2005 for $30 million.

Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.

Aqseptence Group GmbH, part of Chengdu Zhongde Tianxiang Investment Co., Ltd., is a company headquartered in Aarbergen, Germany. The firm manufactures and distributes filtration systems. It was founded by Graf Johannes zu Nassau-Idstein. Baldassare la Gaetana has been the CEO since 2015.\nThe company says this about itself: Aqseptence Group is a leading global supplier of specialized products, equipment and system solutions for filtration & separation and water technology for various applications and unites some of the most renowned brands of the industry, serving industrial and municipal customers for more than 100 years. Our company is headquartered in Germany’s Aarbergen, close to Frankfurt am Main and employs around 1,400 people. We offer a comprehensive range of services to you for the entire value chain – from engineering all the way to startup and maintenance. Our company’s name combines the terms “aqua” and “separation”, thereby referring to our core business separation (and filtration) and water technology. At the same time the name provides an allusion to “competence”. This attribute is an integral part of our company’s ambition and brand personality – describing best what has been driving us for decades.

The Korea Institute of Science and Technology Information (KISTI), Korea (Hangul: 한국과학기술정보연구원; Hanja: 韓国科學技術情報研究院) is a government-backed research institute in Daedeok Science Town in Daejeon, South Korea.

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors. Poseida Therapeutics was founded in 2014 and is headquartered in San Diego, California.

Diversa Corporation is an industrial biotechnology company that develops high performance enzymes. It extracts microbial DNA directly from collected samples to avoid the often impossible task of growing microbes in the laboratory. It mines its collection of microbial genes, numbering in the billions, using high-throughput screening technologies designed to identify unique enzymes as product candidates. Diversa Corporation develops enzymes that are environmentally friendly and more cost-effective for industries such as the global food and fuel markets. It has developed enzymes  to meet the specific needs of companies in various markets, including grain processing, bio fuels, animal health and nutrition and other industries.

Gyrus ACMI, Inc. (doing business as Olympus Surgical Technologies America), part of Olympus Corp., is an American company located in Southborough, MA, that manufactures and sells precision machineries & instruments.

Empa is an interdisciplinary research institute of the ETH Domain for materials science and technology development. It conducts materials and technology research to develop customized solutions for its partners. The institute’s research priorities are structured in five Research Focus Areas (RFA) with the following topics: nanostructured materials, sustainable built environment, health and performance, natural resources and pollutants, and energy. The "Empa Portal" is the contact point for clients and partners who seek solutions to specific problems or who wish to undertake research projects in cooperation with Empa. Empa is headquartered in Dübendorf, Switzerland.

Vindico NanoBioTechnology LLC develops novel and life-saving therapies. The company is headquartered in San Diego, CA.

MyCartis is a privately held immunodiagnostics company, providing next generation solutions to detect and quantify protein biomarker signatures by providing precise and personalized novel clinical information for the benefit of researchers, clinicians and CRO’s. MyCartis’ Evalution® platform with Dynamic Multi-Analyte Technology (DMAT®) inside, provides a unique multiplex biomarker platform in combination with the required sensitivity and dynamic range for the integrated analysis of protein biomarkers. DMAT® utilizes proprietary disk-shaped micro-particles which carry a unique code and can be functionalized with specific proteins, antibodies, nucleic acids or other molecules. Thanks to th

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.